Fatal anaphylaxis in Italy: analysis of cause-of-death national data, 2004-2016 - Bil ò MB, Corsi A, Martini M, Penza E, Grippo F, Bignardi D.
BACKGROUND: Epidemiological data on fatal anaphylaxis are underestimated worldwide. Few Italian data do exist. The aims of the study are to determine the anaphylaxis mortality rate in Italy and its associations with demographic characteristics (gender, age... (Source: SafetyLit)
Source: SafetyLit - May 7, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Families With Food Allergies Struggle With Bare Shelves
As the coronavirus spreads and locked-down communities stock up, products needed by allergy sufferers are increasingly hard to come by. (Source: NYT Health)
Source: NYT Health - April 7, 2020 Category: Consumer Health News Authors: Eric Athas Tags: Peanuts Shopping and Retail Anaphylactic Shock Food Allergies Coronavirus (2019-nCoV) Labeling and Labels (Product) Supermarkets and Grocery Stores Epidemics Quarantines Stockpiling Food and Drug Administration United States Source Type: news
What Causes Tachycardia?
Discussion
Tachycardia is a rapid heart rate that is above normal for age and level of exertion. Tachycardia is common, particularly sinus tachycardia due to normally encountered circumstances such as pain, fever or exercise. It is usually a normal physiologic process but sustained tachycardia often indicates a potentially abnormal underlying cause.
Sinus tachycardia has a rapid heart rate with normal P waves and P-R intervals and variations from moment to moment and respiration. Generally it is not over 200 beats/minute. Vagal stimulation can slow the heart rate; this is a gradual slowing, not an abrupt slowing seen in ...
Source: PediatricEducation.org - March 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Intentional poisoning with peanut as a cause of recurrent anaphylaxis - Robertson K, Kim H.
Anaphylaxis is a serious potentially life-threatening allergic reaction. Most episodes of anaphylaxis are triggered through an immunologic mechanism involving immunoglobulin E (IgE) which leads to mast cell and basophil activation and the subsequent re... (Source: SafetyLit)
Source: SafetyLit - March 10, 2020 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Bioelectronic Research Tackles Hemorrhagic Shock
Jared Huston, MD, a trauma surgeon at Northwell Health on New York's Long Island, spoke straight to the point about the current state of treatment for hemorrhagic shock. While traumatic wounds to extremities can be treated with a tourniquet, such wounds suffered internally are often fatal unless the patient can be transported quickly to an operating room.
"There are no efficacious approaches to treating noncompressible hemorrhage," Huston said. "That's really the problem. If you're injured intra-abdominally or in the chest, and you're not brought somewhere where a trauma surgeon can operate on you and stop the bleeding, yo...
Source: MDDI - February 19, 2020 Category: Medical Devices Authors: Greg Goth Tags: Electronics Source Type: news
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves First Drug To Treat Peanut Allergies In Children
(CNN) — The US Food and Drug Administration approved the first drug to treat peanut allergies in children on Friday, following an advisory committee vote of approval in September.
The drug, Palforzia, can be used for children between 4 and 17 years old. It’s designed to minimize the incidence and severity of a child’s allergic reaction to peanuts, as even a small amount of exposure can be harmful to children with the allergy.
Children are left attempting to avoid exposure to peanuts to avoid reactions. Though that will continue to be necessary with Palforzia, the risk of a reaction will be lessened, says ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 3, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Peanut Allergy Source Type: news
FDA OKs Palforzia, First Drug for Peanut Allergy in Children FDA OKs Palforzia, First Drug for Peanut Allergy in Children
Palforzia will carry a boxed warning on the risk of anaphylaxis, and initial doses can be given only by certified professionals in certified settings.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 1, 2020 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news
FDA approves first drug for treatment of peanut allergy for children
Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals 4 years of age and older. (Source: World Pharma News)
Source: World Pharma News - January 31, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Beta-Blockers, ACE Inhibitors Don ’ t Raise Anaphylaxis Risk From Cardiac Catheterization Beta-Blockers, ACE Inhibitors Don ’ t Raise Anaphylaxis Risk From Cardiac Catheterization
The risk of anaphylactic reactions from contrast media used during cardiac catheterization is not increased in patients on beta-blockers or angiotensin-converting enzyme (ACE) inhibitors, according to results from a retrospective case-control study.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 20, 2019 Category: Radiology Tags: Cardiology News Source Type: news
Errors Common in Epinephrine Use for Pediatric Anaphylaxis Errors Common in Epinephrine Use for Pediatric Anaphylaxis
At least one medication error occurred in two-thirds of epinephrine administrations for simulated pediatric anaphylaxis, even in academic pediatric hospitals, a new international study has found.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 17, 2019 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Delayed admission and management of pediatric acute kidney injury and multiple organ dysfunction syndrome in children with multiple wasp stings: a case series - Ambarsari CG, Sindih RM, Saraswati M, Trihono PP.
Multiple wasp stings may cause fatal complications, such as anaphylactic reactions, intravascular hemolysis, rhabdomyolysis, acute kidney injury (AKI), increased levels of liver enzymes, clotting abnormalities, or even death. AKI-related mortality due to m... (Source: SafetyLit)
Source: SafetyLit - December 16, 2019 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
College student died of allergic reaction to MILK after drinking something with the ingredient
Logan Lewis, 20, a second-year student at Hocking College in Ohio, died after his family says he went into anaphylactic shock when he drank something he didn't know had milk in it. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2019 Category: Consumer Health News Source Type: news
How eating a vegan burger could kill you
The rise in popularity of meat free burgers could leave vulnerable people at risk of suffering an anaphylactic reaction due to the growth in the use of pea protein, experts have warned. (Source: the Mail online | Health)
Source: the Mail online | Health - December 8, 2019 Category: Consumer Health News Source Type: news
Is Peanut Oral Immunotherapy Too Risky? Is Peanut Oral Immunotherapy Too Risky?
A recent study found that peanut OIT was associated with increased risk for anaphylaxis and serious adverse events, but the analysis leaves out some important considerations, says Dr Brian Vickery.Medscape Allergy & Immunology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2019 Category: Consumer Health News Tags: Allergy & Clinical Immunology Commentary Source Type: news
